Eberhard Schlicker

from Wikipedia, the free encyclopedia

Eberhard Schlicker (born December 17, 1952 in Stuttgart ) is a German pharmacologist .

Life

Schlicker studied medicine from 1972 to 1975 at the University of Freiburg and then until 1979 at the University of Heidelberg . In July 1979 he received his doctorate in medicine from Volker Kreye in Heidelberg . From 1980 to 1986 he was a postdoc with Manfred Göthert at the Institute for Pharmacology at the University of Essen and in 1986 a postdoc at the Institute for Pharmacology and Toxicology at the University of Bonn . In the same year he completed his habilitation there in pharmacology and toxicology .

Act

From 1987 to 1992 Schlicker was C2 professor at the University of Bonn and has been an adjunct professor there since 1992; he retired in 2016. The main research areas included the definition of signal recognition molecules ( receptors ) and the analysis of the mechanisms of action in the organism. Particular attention was paid to the identification of presynaptic receptors . The histamine H 3 receptor deserves special mention here; he was able to show for the first time that this receptor occurs on serotoninergic , noradrenergic and dopaminergic neurons in the brain. Some of the studies were carried out by his working group with the groups of Walter Schunack from the Free University of Berlin and Holger Stark from the Heinrich Heine University in Düsseldorf ; In this context, the pitolisant , which has been on the market since 2016, was also examined. A special focus of Schlicker’s work group was the investigation of the endocannabinoid system , partly in collaboration with Andreas Zimmer and Andras Bilkei-Gorzo from the Institute for Molecular Psychiatry at the University of Bonn, partly with Barbara Malinowska from the Medical University in Białystok; the latter cooperation continues. There was also cooperation with colleagues from Poland, namely with Barbara Malinowska from the Medical University in Białystok and Katarzyna Kieć-Konowicz from the University of Krakow, in the investigation of atypical beta-adrenoceptors . Schlicker's research was funded by the German Research Foundation within the framework of individual applications, a research group, a graduate college and the Collaborative Research Center 400 “Molecular Basics of Central Nervous Diseases”. Schlicker is editor of the journal Naunyn-Schmiedeberg's Archives of Pharmacology and deputy chairman of the ethics committee of the University of Bonn; until his retirement he was deputy director of the Institute for Pharmacology and Toxicology at the University of Bonn.

Prizes and awards

Trivia

Schlicker loosened up his seminars and lectures with poems he wrote himself.

Web links

Individual evidence

  1. ↑ Dissertation: Investigations into the biochemical and pharmacological influencing of calcium-45 uptake by microsomes from human umbilical cord arteries .
  2. ^ Habilitation thesis: Presynaptic receptors in the spontaneously hypertensive rat.
  3. ^ E. Schlicker, B. Malinowska, M. Kathmann, M. Göthert: Modulation of neurotransmitter release via histamine H 3 heteroreceptors. In: Fundam Clin Pharmacol . 1994, 8, pp. 128-137, PMID 8020871 .
  4. ^ S. Liedtke, K. Flau, M. Kathmann, E. Schlicker, H. Stark, G. Meier, W. Schunack: Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H 3 -receptor antagonists. In: Naunyn-Schmiedeberg's Arch Pharmacol . 2003, 367, pp. 43-50, PMID 12616340 .
  5. ↑ Pitolisant (Wakix R ), which was developed by a consortium that included W. Schunack and H. Stark as well as Jean-Charles Schwartz, Monique Garbarg and C. Robin Ganellin, is indicated for the treatment of narcolepsy with / without cataplexy .
  6. ↑ M. Kathmann, B. Weber, A. Zimmer, E. Schlicker: Enhanced acetylcholine release in the hippocampus of cannabinoid CB 1 receptor-deficient mice. In: Br J Pharmacol . 2001, 132, pp. 1169-1173, PMID 11250865 .
  7. ↑ M. Feliszek, L. Bindila, B. Lutz, A. Zimmer, A. Bilkei-Gorzo, E. Schlicker: Lack of hippocampal CB 1 receptor desensitization by Δ 9 -tetrahydrocannabinol in aged mice and by low doses of JZL 184. In: Naunyn-Schmiedeberg's Arch Pharmacol . 2016, 389, pp. 603-612, PMID 26984820 .
  8. ^ H. Kozłowska, M. Baranowska, E. Schlicker, M. Kozłowski, J. Laudański, B. Malinowska: Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. In: J Hypertens. 2007, 25, pp. 2240-2248, PMID 17921818 ;
  9. ↑ D. Zelaszczyk, H. Kozlowska, U. Baranowska, M. Baranowska, A. Reutelsterz, K. Kiec-Kononowicz, B. Malinowska, E. Schlicker: Four close bupranolol analogues are antagonists at the low-affinity state of β 1 -adrenoceptors. In: J Physiol Pharmacol. 60, 2009, pp. 51-60, PMID 19439807 .
  10. ↑ E. Schlicker: Poems to loosen up teaching in a theoretical-medical subject (pharmacology). In: Das Hochschulwesen 2014, 62, pp. 68–71.
personal data
SURNAME Schlicker, Eberhard
BRIEF DESCRIPTION German pharmacologist
DATE OF BIRTH 17th December 1952
PLACE OF BIRTH Stuttgart